KamRAB/KedRAB™ is a human rabies immunoglobulin (HRIG) indicated for the treatment of passive,...
- Could groundbreaking gene therapies offer a breakthrough to retinal disease sufferers?
- Could a new gene-editing technology permanently cure Duchenne muscular dystrophy?
- George Washington University to conduct Zika virus trial in Brazil
- Mundipharma EDO initiates Phase I/II oncology trial of tinostamustine in US
- Boehringer and Anthem begin trial to study treatment impact on COPD exacerbations
Visit VelixX at Compamed at booth J19 in Hall 8A
Medicine is becoming an increasingly personalised innovation in medical device technology, moving towards integrated devices that prepare and dose the drugs in one process.
Could groundbreaking gene therapies offer a breakthrough to retinal disease sufferers?
Hereditary retinal disorders are a result of genetic defects, and there are no approved treatments for most of these conditions.
Sartorius Opens New Laboratory Equipment Manufacturing Location
Sartorius has announced the opening of its new 25,000m² facility for the manufacture of laboratory instruments in the industrial zone of Grone in Goettingen.
Could a new gene-editing technology permanently cure Duchenne muscular dystrophy?
Scientists at the University of California, Berkeley, have engineered a new way to deliver CRISPR gene-editing technology inside cells, and have demonstrated in mice that it can repair the faulty gene mutation that causes the severe muscle-wasting disease Duchenne muscular dystrophy.
Verzenio (abemaciclib) for the Treatment of Metastatic Breast Cancer
Verzenio™ (abemaciclib) is a cyclin-dependent kinases (CDK) 4 and 6 inhibitor indicated for the treatment of women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), advanced or metastatic breast cancer.
George Washington University to conduct Zika virus trial in Brazil
The George Washington University (GW) School of Medicine and Health Sciences (SMHS) in the US is set to conduct the clinical trial of an investigational vaccine for prevention of the Zika infection in Brazil.
Mundipharma EDO initiates Phase I/II oncology trial of tinostamustine in US
Switzerland-based Mundipharma EDO has initiated a Phase I/II clinical trial of tinostamustine (EDO-S101) to treat patients with advanced solid tumours in the US.
Boehringer and Anthem begin trial to study treatment impact on COPD exacerbations
Boehringer Ingelheim has initiated a pragmatic clinical trial (AIRWISE) in partnership with Anthem and its outcomes research subsidiary HealthCore to investigate the impact of commonly prescribed medicines on exacerbations of chronic obstructive pulmonary disease (COPD).
Paratek reports positive data from Phase III trial of omadacycline
Paratek Pharmaceuticals has reported positive safety and efficacy data from a Phase III clinical trial (OPTIC) of its investigational antibiotic, omadacycline, for community-acquired bacterial pneumonia (CABP).
Read our magazine
Pharma Technology Focus is the essential reading material for decision-makers in the pharmaceutical industry, bringing you the latest news and analysis in an exciting, interactive format.